

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

HIGHLY POTENT AMYLIN RECEPTOR AGONIST (SYH2092 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the SYH2092 injection (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is an amylin receptor agonist. By optimising its agonistic activity, it has the potential to improve efficacy with a manageable tolerability profile. In addition, through the optimisation of fatty acid modification, it prolongs the *in vivo* half-life which has the potential to translate to a durable weight loss benefit.

Preclinical studies showed that, compared with several amylin analogues currently in clinical development, the Product demonstrated higher target agonistic activity, potent weight-reducing efficacy and a prolonged weight-loss maintenance effect. Furthermore, when used in combination with the glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor dual-biased agonist independently developed by the Group, the Product exerted a synergistic weight-loss effect, increasing the magnitude of weight reduction while prolonging the duration of efficacy.

The Product has the potential to bring significant clinical benefits for weight management in patients with obesity, and improve glycaemic control in adult patients with type 2 diabetes mellitus (T2DM).

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 27 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.